Signature Resources Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Signature Resources Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14	Closed	-$507	–	543
2025 Q1	$507	Sell	14 -1	-7%	-$42	﹤0.01%	361
2024 Q4	$631	Hold	15	–	–	﹤0.01%	348
2024 Q3	$833	Hold	15	–	–	﹤0.01%	342
2024 Q2	$616	Hold	15	–	–	﹤0.01%	380
2024 Q1	$717	Hold	15	–	–	﹤0.01%	363
2023 Q4	$717	Buy	+15	New	+$582	﹤0.01%	364

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Signature Resources Capital Management's RARE Position: Q2 2025 in Review

Signature Resources Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 14 shares — an estimated $507 sold.

Signature Resources Capital Management first reported a position in RARE in Q4 2023 and held it in 6 quarters. The position peaked at $833 in Q3 2024. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

Signature Resources Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Signature Resources Capital Management sold 14 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $507.
Signature Resources Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 6 quarters.
Signature Resources Capital Management's Ultragenyx Pharmaceutical position peaked at $833 in Q3 2024.
309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Signature Resources Capital Management's 13F filing for Q2 2025, filed 16 Jul 2025.